Floatz logo

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter

Platinum-Resistant Ovarian Carcinoma

Mayo Clinicgene_therapyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

244 Active assets in the Platinum-Resistant Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter is also rated in:

primary peritoneal carcinomaDormant
B
Indicative ·
63 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
B
Indicative ·
59 / 100
View asset →
fallopian tube mucinous adenocarcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →